 | | Vol. 12.25 – 29 June, 2023 |
| |
|
|
| Researchers presented a uniquely large dataset screening over 5000 targeted agent combinations across 81 NSCLC lines. Their analysis revealed a profound heterogeneity of response across the tumor models.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators explored the potential therapeutic effects and molecular mechanisms of amifostine on bleomycin (BLM)-induced pulmonary fibrosis in mice. A mouse model of pulmonary fibrosis was established using BLM.
[Scientific Reports] |
|
|
|
| Scientists found that follistatin-like 1 (FSTL1) expression was upregulated in the lung tissues of patients with idiopathic pulmonary fibrosis and that SENP1 was overexpressed in senescent alveolar epithelial cells.
[Cell Biology International] |
| |
|
|
| Researchers reported a small-molecule inhibitor of OTUD3 (OTUDin3) by computer-aided virtual screening and biological experimental verification. OTUDin3 exhibited pronounced antiproliferative and proapoptotic effects by inhibiting deubiquitinating activity of OTUD3 in NSCLC cell lines.
[Cell Death & Disease] |
|
|
|
| Associations with clinicopathologic features, survival, and the prognostic value of miR-375 in lung squamous cell carcinoma were clarified in a retrospective study of 90 pairs of LUSC tissues. In vitro and in vivo gain- and loss-of-function assays were conducted to validate the effects and mechanism of miR-375.
[Cell Death Discovery] |
|
|
|
| Researchers characterized the proliferation, expression of proinflammatory cytokines, activation profile, and lysis capacity in co-cultures with A549 lung carcinoma cells with and without transforming growth factor (TGFβ) neutralizing antibodies.
[Respirology] |
|
|
|
| Scientists showed that NSCLC cell lines have heterogeneous metabolic profiles, which may be underlaid by different genetic profiles, revealing an opportunity to identify and stratify patients who can benefit from metabolism-targeted therapies.
[Lung Cancer] |
|
|
|
| Hypoxia upregulated PRMT5 expression in lung cancer cells. Additionally, PRMT5 overexpression promoted cancer cell resistance to carboplatin.
[Cell Biology International] |
|
|
|
|
| The authors provide a comprehensive overview of the mechanisms that limit the efficacy of KRASG12C inhibitors and review potential strategies to overcome and possibly delay the development of resistance in patients receiving KRAS-directed targeted therapies.
[Current Oncology Reports] |
|
|
|
|
| BioNTech SE announced that the first patient with NSCLC has been treated in a pivotal Phase III trial evaluating the companies’ next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392.
[BioNTech SE] |
|
|
|
|
| July 24 – 28, 2023
Boston, Massachusetts, United States |
|
|
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
| | University of Texas at Austin – Austin, Texas, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | Pfizer, Inc. – Southern California, United States |
|
|
|
| | King’s College London – London, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
